|Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients|
|Ji, Dengbo1; Qiao, Meng1; Yao, Yunfeng1; Li, Ming1; Chen, Hailong2; Dong, Qi2; Jia, Jinying1; Cui, Xinxin1; Li, Zhaowei1; Xia, Jinhong1; Gu, Jin1,3,4|
|关键词||Serum-based microRNA signature Colorectal cancer Adjuvant chemotherapy Prognostic biomarker|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal ; Medicine, Research & Experimental|
|研究领域[WOS]||General & Internal Medicine ; Research & Experimental Medicine|
|关键词[WOS]||COLON-CANCER ; CIRCULATING MICRORNAS ; PROGNOSTIC BIOMARKER ; PLASMA MICRORNAS ; EARLY-DIAGNOSIS ; SURVIVAL ; PROTEIN ; MIR-21 ; CELLS|
Background: Approximately 60% of patients with colorectal cancer (CRC) undergo either local recurrence or distant metastases after surgery. Current prognostic biomarkers are insufficient to predict recurrence of CRC and provide little forecast information about what patients are likely to receive benefit from the adjuvant chemotherapy. As microRNAs (miRNAs) constantly exist in human serum and being used to predict the prognosis of a various cancers, this study was designed to identify miRNA-based circulating biomarkers to predict clinical outcomes of CRC.
Methods: A serum-focused miRNA expression was used to investigate if miRNA expression profiles could predict the clinical outcomes of patients with CRC. We created miRNA signature profiles associated in the training set (n = 40), and further validated its prediction in two independent testing cohorts.
Results: Using Cox regression and risk-score analysis, we identified a four-miRNA signature (miR-652-3p, miR-342-3p, miR-501-3p and miR-328-3p) for the prediction of tumor relapse and the overall survival(05) of patients with CRC in the training set (n = 40). This miRNA signature was further validated in a testing set (n = 226) and another independent cohort (n = 56). A high-risk signature score was significantly associated with CRC tumor recurrence and poor treatment outcome. Multivariable Cox regression models indicated that the risk score, based on the four-miRNA signature, was an independent prognostic classifier for patients with CRC.
Conclusions: The scrum miRNA signature may serve as a minimally invasive predictor for tumor relapse and treatment outcome in patients with CRC and provide a useful reference for treatment selection. (C) 2018 The Authors. Published by Elsevier B.V.
|作者单位||1.Peking Univ, Dept Gastrointestinal Surg 3, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China;|
2.Zhejiang Univ, Key Lab Mol Biol Med Sci, Key Lab Canc Prevent & Intervent,Sch Med, Canc Inst,China Natl Minist Educ,Affiliated Hosp, Hangzhou 310009, Zhejiang, Peoples R China;
3.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China;
4.Peking Univ, SG Hosp, Beijing, Peoples R China
|Ji, Dengbo,Qiao, Meng,Yao, Yunfeng,et al. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients[J]. EBIOMEDICINE,2018,35:189-197.|
|APA||Ji, Dengbo.,Qiao, Meng.,Yao, Yunfeng.,Li, Ming.,Chen, Hailong.,...&Gu, Jin.(2018).Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.EBIOMEDICINE,35,189-197.|
|MLA||Ji, Dengbo,et al."Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients".EBIOMEDICINE 35(2018):189-197.|